Advanced Models for Target Validation & Drug Discovery in Prostate Cancer by Malin Åkerfelt et al.
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1. Introduction 
Prostate cancer (PrCa) is one of the most prevalent malignant diseases among men in Western 
countries. Despite good initial treatment response is observed in the vast majority of PrCa 
patients, tumor relapse is observed in about 7-10% of patients undergoing standard anti-
hormonal therapies with anti-androgens and/or GnRH antagonists. There is currently no cure 
for castration-resistant prostate cancer (CRPC), and median survival for these patients is only 
about 18 months. The high mortality rate of advanced cases is closely associated with invasive 
carcinomas and systemic metastasis, most frequently to the bone; and CRPC is almost always 
coincident with overexpression/amplification of the androgen receptor (AR) gene. CRPCs fail 
to respond to all currently prescribed first line anti-hormones such as flutamide, nilutamide or 
casodex (bicalutamide). The second line anti-tumor treatment against CRPC, frequently 
taxanes like docetaxel, is administered to patients after the first or second relapse. Taxanes are 
often supported by zoledronic acid targeting bone metastases. These drugs and drug 
combinations are in most cases initially effective, but rarely curative. Although taxanes do 
show potent anti-tumor effects, advanced PrCa patients develop resistance and only gain 
several months of survival time. For decades, no major improvements have been made in the 
therapy of advanced PrCa. However, this situation has dramatically changed over the last few 
years with a number of novel, promising drug concepts in the pipeline, some of which have 
already entered the market. It is not expected that these drugs will be curative, and relapses 
and therapy failures are expected to develop in these cases which may remain fatal. Therefore, 
the demands will remain high to develop yet better drugs, and more faithful models that 
reliably mimic at least some of the key aspects of advanced prostate cancers. These models are 
required to recapitulate the mechanisms leading to therapeutic resistance & failure also for 
new compounds and drug combinations entering the clinics now. There will remain a need to 
mimic which mechanisms either in the tumor cells or in the tumor-associated 
microenvironment may have contributed to the resistance. This consistent high demand in 
improved models will go hand in hand with a better understanding of the pros and cons of the 
various models available. Continued development of improved model systems for PrCa and 
in particular CRPC could lead to an informed ranking according to the maximal throughput in 
drug screens that can be achieved, balanced against their true informative value and relevance 
for recapitulating clinical PrCa. A systematic side-by-side comparison of available models, e.g. 
cell lines, organotypic three-dimensional cultures and co-cultures, xenografts, tissue 
www.intechopen.com
 Prostate Cancer – From Bench to Bedside 
 
54
recombination techniques and genetically engineered mouse models (GEMMs) is still 
missing. Furthermore, model development in PrCa is significantly lagging behind the 
advances in other fields, primarily breast cancer. Here, a considerably larger body of 
literature, methods, and better understanding of the pre-clinical models has been achieved, 
owing in part to innovative technologies such as 3D organotypic cultures and 3D tumor 
growth assays. Although prostate and breast cancer share many biological and histological 
properties and features, they remain fundamentally different diseases with different 
molecular pathways leading to transformation and progression. Modeling PrCa and in 
particular CRPC requires dedicated and specialized model development, coupled with a 
thorough characterization thereof. 
In line with the relative lack of reliable PrCa models, and in contrast to other epithelial 
cancers, only a relative small number of molecular targets other than androgen receptor 
(AR) and AR-associated genes have been identified and validated in CRPCs (Feldman & 
Feldman, 2001). Even gene expression profiles of clinical prostate cancer samples were 
lagging behind studies related to e.g. breast cancers or gliomas, in particular 
characterization of advanced and metastatic lesions has been missing. Only recently, 
comprehensive large-scale transcriptome studies (> 250 clinical samples), combined with 
other levels of genetic analyses such as miRNA expression, next-generation sequencing, and 
analysis of mutations & copy number changes, have become available (Taylor et al., 2010). 
These studies will be invaluable for target identification and bioinformatic network analyses 
of PrCa’s. Similarly, the identification of potent drugs that could block AR functions in 
CRPCs, such as novel synthetic anti-androgens, was mainly based on a relative small panel 
of largely reductionist models and cell lines (van Bokhoven et al., 2003a; 2003b). This 
situation has only slightly improved after the generation of a panel of new, more 
informative cell lines in the 1990’s, and remains a key problem in PrCa research.  
Additionally, many of the routine models for the pre-clinical phase of drug development are 
greatly insufficient, and fail to recapitulate key aspects of the molecular and biologic 
diversity of PrCa. For example, many PrCa cell lines actually lack expression of key 
molecular components such as AR or the critical ETS fusion factors. Furthermore, in 
particular in the early stages of pre-clinical research and cell-based screens, cell lines are 
routinely cultivated in monolayer on plastic. This does not support formation of 
extracellular matrix (ECM) nor relevant cell-cell interactions and epithelial differentiation 
processes to occur. Cell-cell-contacts formed by cells on plastic are of temporary nature, and 
fail to properly recapitulate differentiation and maturation programs intrinsic to epithelial 
cells. A key feature of both breast and PrCa is the capacity to undergo “acinar 
morphogenesis”, i.e. the formation of functional glandular spheroids and tubular structures 
that connect such organoids. These are a key element of epithelial plasticity and contribute 
to cell motility and invasiveness (branching, spreading). No such features can be observed 
in monolayer cultures, depriving otherwise even potentially informative model systems of 
biological relevance. To overcome these shortcomings, organotypic cultures of breast and 
prostate cancer cell lines have been investigated since the early 1970’s.  
Cells can also be embedded in artificial or natural matrices or scaffolds. This provides an 
altogether different biology that has very little resemblance to the “floating” spheroids 
formed in non-adherent cultures, apart from the often equally rounded overall shape. 
Spheroid cultures or PrCa cells embedded in extracellular matrices have been systematically 
explored since 2001 (Bello-DeOcampo et al., 2001; Lang et al., 2001). This was again lagging 
behind the breast cancer field, in which such efforts were initiated in the 1990’s (Streuli et al., 
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1991; Weaver et al., 1995; Weaver et al., 1996). Later studies introduced a focus on tissue 
differentiation, morphogenesis and imaging (Debnath et al., 2003; Debnath & Brugge, 2005; 
Mailleux et al., 2008). The development of defined scaffolds/matrices is ongoing, although 
the most widely used material remains Matrigel. This is derived from a mouse sarcoma cell 
line that produces large amounts of laminin-rich ECM.  
However, the most important shortcoming of currently available models for PrCa and 
CRPC is the lack of complexity that is recapitulated by mono-culture of a single cell type, 
usually the tumor cells. These do not act as singular entities and a carcinoma in fact 
represents a disturbed, but nevertheless complex tissue with its own regulation of tissue 
homeostasis. Tumor and stromal cells (in combination with ECM components such as 
laminins and collagens) are the main actors in tissue formation, followed by smooth muscle 
or myoepithelial cells and invading components of the immune system (Fig. 1). The 
development of co-culture systems of tumor cells with relevant tumor-associated or normal 
fibroblasts has not yet left the developmental phase. Despite a large number of different 
approaches, there is no consensus which of these models would be particularly informative 
and relevant. Most of the co-culture models may not be highly reproducible and remain 
only poorly standardized. Thus, more reliable models to study tumor-host interactions and 
the role of the stromal compartment in development and progression of PrCa are still much 
in demand. Also the role of tumor stroma in mouse xenografts is debated. 
 
 
Fig. 1. Anatomy of prostate cancer. In low-grade tumors, cancer cells are still enclosed by intact 
basement membrane. The interstitial ECM is composed of fibrous proteins such as collagens, 
glycosaminoglycans and fibronectin. The cellular part is formed by fibroblasts, smooth muscle 
cells, myoepithelial cells, endothelial cells and invading actors of the immune system. 
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As a result, a lack of understanding of key molecular events in tumor progression to 
metastatic, invasive prostate cancers (CRPC) remains. Most models lack the required 
complexity, but also relevant high throughput capacities required for early stage pre-clinical 
research. Furthermore, most complex experimental systems are not cost effective. Many of 
the basic tools required for high content or high-throughput cell-based screening (HTS), 
such as miniaturization, automation, and reliable readout systems are in a rudimentary 
state. Furthermore, those few model systems that allow higher throughput, may not be very 
representative for prostate cancer biology and differentiation. Such experimental systems 
are typically based on floating “prostaspheres” or organoids/microtissues; these, however, 
do not undergo significant differentiation processes. Only very few, matrix-embedded 
organotypic models are available for HTS. Apart from the lack of biological relevance of 
many experimental systems, it also remains generally difficult to transfer informative model 
systems across different laboratories. Together, these eminent insufficiencies may explain 
why preclinical studies are too often poorly predictive for the outcome of clinical trials, and 
why many of these trials eventually fail – typically in stage II or III. Generally, for a new 
compound to be synthesized and approved on the market it takes about 10 years or more, 
costing billions of dollars, and the number of FDA approved drug has steadily decreased 
during the last few years. At this point of the clinical drug discovery pipeline, a large sum of 
money has already been invested. Parts of it could have been saved, provided the target 
validation strategy had been more informative and pre-clinical models utilized had been 
more predictive. Therefore, it is critical for future drug development to integrate multiple 
efforts, models and target validation strategies into a more comprehensive approach. 
Only a broader spectrum of biologically relevant models allows thorough exploration of key 
mechanisms involved in therapy failure, and to focus on the major pathways involved in 
progression to CRPC. Furthermore, it will be mandatory to include the essential aspects of 
tumor-host cell interactions and tumor cell heterogeneity. This chapter will give an 
overview of the most relevant cell-based model systems currently available. We will mainly 
focus on in vitro cell culture models with an excursion into the wide field of orthotopic and 
subcutaneous xenografts. Only some selected examples for GEMMs that have been recently 
developed will be addressed here, in close connection to the cancer mechanisms and 
pathway they are modeling. Excellent reviews on mouse models of PrCa in general 
(Hensley & Kyprianou, 2011; Park et al., 2010) and GEMMS in particular (Jeet et al., 2010; 
Wang, 2011) have been published recently. According to this, we felt an overview of the 
status of ex vivo models may be timely, as this field is rapidly evolving and has not been 
widely reviewed. The most urgent unmet needs apply for the research related to fatal, 
under-treated CRPC. Our focus will therefore be mainly on the molecular pathways 
involved in progression to CRPC. Our aim is to discuss how advanced models may help to 
address improve target validation and drug discovery particularly in CRPC. 
2. Target Validation: Modelling pathways and mechanisms in castration-
resistant prostate cancer (CRPC) 
2.1 Modeling AR modifications in CRPC 
AR functions remain critical in essentially all CRPCs. AR is the target of genetic DNA 
amplifications leading to its overexpression (Koivisto et al., 1997; Visakorpi et al., 1995), as 
well as function-modifying point mutations. DNA amplifications targeting the AR locus 
result in overexpression of AR in up to 30% of the patients. Gain-of-function mutations of 
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AR (20-30% of patients) enable AR to bind a broad spectrum of steroidal and non-steroidal 
molecules as agonists (Koivisto et al., 1999; van de Wijngaart et al., 2010). Functionally 
relevant AR modifications include also changes in co-regulatory molecules such as nuclear 
co-activators and repressors. Additionally, alterations of signaling cascades that lead to 
activation of AR independent of ligand(s) have been described (reviewed in (Scher & 
Sawyers, 2005). In combination, these modifications are the most critical molecular 
mechanism that renders CRPCs independent of physiological levels of androgens. CRPCs 
thrive on significantly reduced levels of androgens or utilize alternative ligands that are more 
readily available. In some cases, AR mutations may render PrCa cells completely independent 
of external ligand supplies and the tumors develop an entirely independent, self-sufficient AR 
signaling axis – although AR still remains the main target. Ligand-independent and ligand-
mediated functional activation of AR is reflected by phoshorylation, subsequent nuclear 
import (Jenster et al., 1993), and transcriptional activation of AR target genes such as PSA 
(prostate-specific antigen). While PSA and other classic AR-controlled genes remain mostly 
driven by AR, the overall spectrum of AR-responsive genes is often greatly altered and 
expanded in advanced cancers (Wang et al., 2009a). This observation has only recently 
changed the basic understanding of CRPC biology. 
Upon failure of primary therapy, anti-androgens such as casodex, flutamide or nilutamide fail 
to block AR and/or start promoting cell proliferation instead. These antagonists often convert 
to agonists (activators) of AR signaling, a poorly understood mechanistic complication (Dahut 
& Madan, 2010) - for which few experimental model systems exist. Many AR mutations 
described in patients confer gain-of-function properties. In the clinics, the conversion of anti-
androgens and tumor relapse is reflected in a sudden steep increase of PSA levels. 
Nevertheless, PSA rise as such is only poorly indicative of patient survival and fails to predict 
response or failure of therapy. Instead of PSA, scintigraphy and PET imaging have turned out 
to be more reliable. However, the most promising method may be the detection of circulating 
tumor cells (CTCs) (Attard et al., 2009; Danila et al., 2010; Danila et al., 2011). CTCs typically 
contain the same cancer-relevant mutations as the primary tumor, e.g. amplified/mutated AR. 
These features can be utilized for further characterization and fine tuning of diagnostic tools 
(Attard et al., 2010; Zhang et al., 2010). However - the role of CTCs in forming distant 
metastases and relapse is only poorly understood. No good models are available that would 
dynamically mimic the systemic spread of PrCa cells. For example, xenografts rarely produce 
metastatic lesions  to the bone, which represents the most frequent metastatic site in humans. 
Additionally, detection of small metastatic lesions by in vivo imaging is technically difficult 
(van Weerden et al., 2009), and may require removal of the primary tumor to allow monitoring 
the metastases. In vivo imaging may also suffer from extremely dynamic cell behavior in vivo: 
small lesions spontaneously disappear and reoccur at other locations, with few lesions able to 
successfully maintain themselves. It remains unclear how well these animal models represent 
the acute human problem of developing metastatic CRPC (Eaton et al., 2010). Major 
improvements in the use of light-emitting cell lines and more sensitive detection methods may 
help to overcome these difficulties in the future. Even more important would be the generation 
of reliable cell line models that effectively form metastatic lesions in mouse models – ideally 
utilizing mechanisms similar to human systemic spread.  
Until very recently, little progress was made in the development of novel anti-androgens. 
The most exciting new entities, MDV3100, its derivative RD162 and TAK-700, were recently 
demonstrated as superior to casodex in castration-resistant LNCaP-AR xenograft models. 
Both MDV3100 and TAK-700 were also successful in clinical studies (Attard et al., 2011; 
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Chen et al., 2009; Massard & Fizazi, 2011; Tran et al., 2009). A phase I/II multi-center first-
in-man trial of MDV3100 was recently completed (Scher et al., 2010), and a regulatory 
phase III trial with advanced PrCa patients previously failing taxane therapy has started 
in 2010. According to preliminary clinical data, MDV3100 does not quickly develop 
agonism to AR in CRPCs, and shows a more consistently and robust antagonist activity 
clearly superior to casodex. The still limited potential of these drugs is reflected in the 
possibility to generate MDV3100 resistant cell clones, e.g. in vivo by continued daily 
treatment of mice followed by serial passage of LNCaP/AR xenografts, or in vitro by 
using VCaP cells and long term drug exposure. In the majority of these resistant clones, 
AR expression is maintained. This is likely to happen in relapsed tumors from future 
clinical use. As expected, MDV3100-resistant CRPC cells remain dependent on continued 
AR signaling as demonstrated by siRNA knockdown: Not even the most advanced novel 
drugs are capable of breaking this addiction. In conclusion, novel drugs like Orteronel 
(TAK-700) and MDV3100 are unlikely to be curative, and will result in relapse and further 
progression with yet unknown frequency and time course. To explore the putative 
molecular mechanisms of MDV3100 or TAK-700 resistance in the future will require a 
very systematic approach and the use of a comprehensive panel of complementary 
models. There will also be a need to systematically address the impact of the tumor 
microenvironment and the stromal counterpart, using organotypic and co-culture models. 
These interactions are expected to considerable contribute to the development of late 
stage drug resistance, compared to treatment of primary tumors.  
CRPC tumors may gain the capability to metabolically synthesize sufficient levels of 
androgens, which renders the tumors completely independent of endocrine hormone 
supplies (testis, adrenal gland). The drug abiraterone acetate, recently approved by the FDA 
for treatment of advanced CRPC, (Agarwal et al., 2010; de Bono et al., 2011; Molina & 
Belldegrun, 2011), blocks the formation of androgens by inhibiting CYP17A1 (17α-
hydroxylase/17, 20 lyase). This metabolic enzyme is involved in the formation of DHEA 
and androstenedione. These intermediates are then further metabolized to testosterone 
(Attard et al., 2009a; Attard et al., 2009b). Like MVD3100 and TAK-700, abiraterone showed 
promising results in phase I-III clinical trials (Ryan et al., 2010; Shah & Ryan, 2010; Sharifi, 
2010), but the response rate is equally incomplete and was approved by the FDA in April 
2011. Abiraterone is also expected to result in resistances, with mechanisms that are very 
likely to involve the tumor microenvironment (stromal cells, endocrine factors and 
myoepithelial/smooth muscle cells). For example, the stromal cells may actually be 
responsible for developing resistance, subsequently providing significant levels of 
androgens to nearby tumor cells.  
Nevertheless, recent success stories only illustrate that AR remains the fundamental target 
in PrCa, essentially throughout all stages of progression. Nevertheless, the novel drugs also 
demonstrate that it is possible to temporarily block AR or androgen functions even in CRPC. 
How well these new drugs will improve the efficacy of CRPC treatment, will be shown in 
the future. Understanding both the mechanisms of action & pathways leading to the 
expected resistance in tumor cells will require more than ever the use of a panel of advanced 
prostate cancer models. More detailed understanding of AR-related signaling pathways and 
an improved, contextual target validation will have the potential to significantly improve 
therapy and patient outcome. Ideally, this will include exploring the potency of combination 
therapies with older concepts, such as ketoconazole (Figg et al., 2010; Peehl et al., 2002; Ryan 
et al., 2010) or prednisone (Danila et al., 2010).  
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The insight that PrCa progression to CRPC is intricately associated with hyperactive 
androgen signaling was recently demonstrated by the generation of a mouse model based 
on an activating AR mutation (T877A), which was overexpressed in prostatic epithelial cells 
by targeted somatic mutagenesis. ARpe-T877A mice formed hypertrophies and eventually 
carcinomas (Takahashi et al., 2011). Tumor progression was greatly enhanced by 
overexpression of Wnt-5a that served as an activator. These findings suggest that mutant AR 
alone may already provide tumor-promoting properties which are further potentiated by 
additional genetic alterations. Such novel and exciting transgenic mouse models for PrCa 
may become very powerful tools in future pre-clinical trials (Jeet et al., 2010; Wang, 2011).  
2.2 Modeling ETS fusion transcripts in PrCa & CRPC 
AR may be the key player in PrCa progression but is certainly not acting in isolation. This 
was recently demonstrated by the discovery of TMPRSS2-ETS factor fusion genes that can 
be attributed to 40-60% of all PrCa (Tomlins et al., 2005; Tomlins et al., 2006; Tomlins et al., 
2007; Tomlins et al., 2008). Other ETS fusion factors such as ETV1 and ETV4 (Hermans et al., 
2008a; Hermans et al., 2008b) were soon following. The panel of ETS fusion rearrangements 
and driver genes/promoters is still growing, although the most frequent and relevant 
translocation is the TMPRSS2-ERG event. The occurrence of TMPRSS2-ETS factor fusion 
events is considered an important initiating event in PrCa tumor progression (Mosquera et 
al., 2008; Perner et al., 2007; Saramaki et al., 2008), but is not sufficient to fully transform 
benign prostate cells. This has been demonstrated by the fact that ETS fusion genes also act 
as tumor-initiating factors in transgenic mouse models (Brenner et al., 2011; Carver et al., 
2009a; Carver et al., 2009b), but generally require cooperative oncogenic events such as 
haplo-insufficiency or complete loss of PTEN and activation of c-Myc (Sun et al., 2008) for 
progression to invasive carcinomas. Apart from the tumors, ETS fusion gene transcripts 
have also been detected in clinical pre-malignant lesions such as HGPIN (high grade 
prostatic intraepithelial neoplasias). Surprisingly, TMPRSS2-ERG expression is frequently 
associated with a favorable prognosis (Hermans et al., 2009; Saramaki et al., 2008). Thus, ETS 
factor fusion genes events may represent cancer-initiating events, but might not critically 
contribute to tumor progression and CRPC. Also in clinical PrCa, ETS factors may need to 
cooperate with additional oncogenic events such as PI3Kinase pathway activation, loss of 
one allele of PTEN and AR amplification (King et al., 2009; Squire, 2009; Yu et al., 2010), 
which are considered key factors for tumor progression. However, this topic remains 
controversial: Duplication of the TMPRSS2-ERG fusion gene locus was associated with 
worsened prognosis and progression towards advanced CRPC (Attard et al., 2008; Attard et 
al., 2010). This also makes sense, as ETS fusion events are strictly androgen-responsive and 
require functional AR, which links ETS factors intimately to AR biology. Accordingly, 
TMPRSS2-ERG fusion gene expression is massively re-activated in CRPC tumors (Cai et al., 
2009), concomitant with the over-expression of androgen-dependent genes like PSA. Thus, 
appropriate models for CRPC and the role of AR should not underestimate the contribution 
of ETS fusion genes, and their function cannot be clearly functionally separated from AR 
signaling. Only a small fraction of PrCa cell lines that contain actively transcribed ETS 
fusion transcripts have been described, such as the VCaP and DuCaP lines (Korenchuk et al., 
2001). These cell lines harbor the characteristic AR amplification. Both VCaP and DuCaP, 
established from different metastatic lesions of the same patient, represent excellent models 
for both CRPC and ETS-factor positive PrCa. Nevertheless, these cell lines do not readily 
form metastatic lesions in xenograft mouse models (Havens et al., 2008; Loberg et al., 2007; 
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van Golen et al., 2008) nor do they belong to the most straightforward cell lines to grow in 
the laboratory – which somewhat limits their value. More advanced, aggressive models for 
CRPC based on VCaP cells have been generated using mouse xenografts (Loberg et al., 
2006a; Loberg et al., 2006b). Apart from VCaP, only the NCI-H660 cell line contains another 
TMPRSS2-ERG fusion event (Mertz et al., 2007). But NCI-H660 is not a typical “luminal” 
PrCa cell line and lacks expression of AR, which renders this model rather irrelevant for 
many aspects of CRPC. This line was initially described as a small-cell lung carcinoma 
before it was reclassified as the metastasis of a prostate small-cell carcinoma. NCI-H660 may 
represent a model for the neuroendocrine differentiation phenotype, which is sometimes 
observed in PrCa. Furthermore, the classic castration-resistant, androgen-responsive LNCaP 
cell line contains a rearranged ETV1 fusion gene. However, ETV1 is not functionally 
expressed and LNCaP therefore not a very relevant model for ETS factor biology. Loss of 
ETV1 expression may indicate that this gene is not required for progression to CRPC. In 
summary, it is surprising that ETS fusion events appear to be under-represented in 
established PrCa cell lines. This observation may be related to particular difficulties to 
establish ETS-factor positive PrCa lines from clinical tumor material. The diagnosis of ETS 
factor fusion genes in PrCa have only now begun to affect clinical practice and diagnostics 
(Laxman et al., 2008; Tomlins et al., 2009), although detection of fusion events may soon 
become a routine technique (Hu et al., 2008; Jhavar et al., 2008; Mao et al., 2008). As of yet, 
the discovery of ETS fusion genes has also not resulted in many novel and useful 
therapeutic concepts (Björkman et al., 2008), although the first functional insights may yet 
have to be followed up and clinically translated (Gupta et al., 2010; Mohamed et al., 2011; 
Yu et al., 2010). A lack of appropriate models that faithfully mimic the biology of ETS 
fusions in the context of PrCa and CRPC may have contributed to the relative slow 
progress in this field.  
2.3 Modeling molecular pathways beyond AR: PTEN, PI3 kinase and AKT 
Alternative pathways for ligand-independent activation of AR are discussed as key 
mechanisms in at least a subset of CRPC. However, the kinases suggested to be involved, 
their clinical relevance, and the number of cases affected are still highly debated. Insights 
from large-scale tumor sequencing efforts such as the Sanger Institute (COSMIC database of 
somatic mutations in cancer; http://www.sanger.ac.uk/perl/genetics/CGP/cosmic) have 
identified candidate genes that are most frequently mutated in PrCa. According to this 
database (Status July 2011), p53 mutations are the most frequently found somatic alterations 
(19%), followed by PTEN (14%), and KRAS mutations (7%). Mutations in all three ras genes 
(HRAS, KRAS, NRAS) together account for about 13% of PrCa cases. Other frequent 
mutations, pointing essentially to the same key molecular pathways involved in prostate 
cancer progression, are EGFR (7%), beta-catenin (CTNNB1; 6%), Retinoblastoma (RB, 6%) 
and B-raf (4%). The frequencies for PTEN are significantly higher if genetic deletions (LOH) 
and rearrangements are also taken into account. Loss of one allele of PTEN is the most 
frequent genetic alteration in primary PrCa, while loss of both PTEN alleles is frequently 
observed in advanced CRPC. This genetic background information is critical to evaluate the 
biological relevance of models for PrCa and CRPC.  
PTEN (phosphatase and tensin homolog deleted on chromosome 10) and the downstream 
PI3 Kinase (PI3K) and AKT pathways are closely linked to CRPC. PTEN loss and 
perturbation of these pathways have been implicated in early stage prostate carcinogenesis 
(Zong et al., 2009) as well as late stage CRPC (Verhagen et al., 2006; Vlietstra et al., 1998). 
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PTEN negatively regulates the activity of AKT and PI3K pathways. Loss of one or both 
alleles of PTEN increases the intracellular levels of the second messenger PIP3 and results 
in constitutive activation of AKT. PI3K promotes the activation of AKT at Thr308 via the 
kinase PDK1, followed by a second phosphorylation step by PDK2 at Ser473. AKT then 
translocates into the nucleus and triggers many cell survival mechanisms, promotes cell 
cycle progression, and possibly invasion (reviewed in (Sarker et al., 2009)). Oncogenic, 
activating AKT mutations and gene amplifications have been described (Boormans et al., 
2010). AKT’s role as a primary survival factor may significantly contribute to the 
development of CRPC and therapy failure. Furthermore, PI3K and AKT are important 
pathways for the maintenance of PrCa stem cell populations (Dubrovska et al., 2009; 
Korkaya et al., 2009; Sarker et al., 2009) and stem cell survival. The PI3K pathway 
cooperates with other important proto-oncogene such as c-Myc (Clegg et al., 2011) in PrCa 
and model systems, and promotes cancer progression in both. Receptor tyrosine kinases 
(RTKs) like EGF Receptor, Her2/ERBB2, c-MET or IGF1R, as well as non-RTK’s, also 
result in the activation of PI3K and AKT. Therefore, frequent observation of EGFR 
mutations in PrCa’s functionally contributes to the same clinically relevant pathways, as 
do s Ras and B-raf mutations, which are downstream signaling cascades. PTEN loss, AKT 
and PI3K pathways have been functionally associated with ligand-independent AR 
activation mechanisms, but conclusive validation and precise functional details e.g. in 
clinical tumors are clearly missing. AKT may interact with and contribute to the ligand-
independent phosphorylation of AR in CRPCs (Shen & Abate-Shen, 2007). Gain of 
function mutations in the PI3K pathway, primarily mutations of PIK3CA, are also the 
most frequent genetic mutation in breast cancers (Samuels et al., 2004), and occur 
sporadically in PrCa (< 1%). 
Tissue-specific knock-out of a single allele of PTEN in mice promotes the formation of 
hyperplastic lesions but not carcinogenesis, (Korsten et al., 2009; Liao et al., 2010c). Haplo-
insufficiency of PTEN strongly requires cooperation with additional tumorigenic events 
such as TMPRSS2-ERG fusion genes (Carver et al., 2009b; King et al., 2009; Squire, 2009), loss 
of NKX3.1 (Song et al., 2009), p53 mutations (Abou-Kheir et al., 2010; Couto et al., 2009), 
STAT3 (Blando et al., 2011), and AR overexpression. Loss of PTEN in the mouse prostate 
epithelium is generally insufficient to generate malignant lesions in transgenic mouse 
models (Couto et al., 2009), and typically results only in the formation of pre-malignant 
hyperplastic lesions. Interestingly, PTEN inactivation in mouse models without supporting 
additional events may primarily result in a specific form of senescence, which can be readily 
overcome by p53 knock-down (Alimonti et al., 2010). The resulting tumor cells show a 
dramatically increased stem- or progenitor cell and self-renewing potential (Dubrovska et 
al., 2009; Korkaya et al., 2009; Mulholland et al., 2009). It is also possible to isolate PTEN (-
/+) mouse PrCa cell lines from primary tumors for molecular follow-up studies (Jiao et al., 
2007; Liao et al., 2010c), and to further genetically modify these cells for generating 
androgen-independent CRPC lines. This includes the stromal compartment, which can also 
be extracted from transgenic mice and used for sophisticated tissue recombination and 
grafting experiments (Liao et al., 2010a; Liao et al., 2010b). Tissue recombination, e.g. 
combining mouse urogenital mesenchyme cells, or tumor-associated fibroblasts are a 
powerful model to explore tumor-host interactions and tumor microenvironment (Liao et 
al., 2010a). Cells from genetically engineered mouse models (GEMMs) can be further 
propagated in spheroid or 3D cultures, which may enhance the stem cell character of the 
resulting clones (Liao et al., 2010b). 
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The requirement for additional oncogenic events is also exemplified in mice in which loss of 
PTEN is combined with over-expression of the TMPRSS2-ERG fusion oncogene (Carver et 
al., 2009b) or loss of NKX3.1 (Song et al., 2009). NKX3.1 (-/-) PTEN (+/-) mice 
spontaneously develop androgen-independent lesions following castration (Abate-Shen et 
al., 2003; Gao et al., 2006; Kim et al., 2002; Ouyang et al., 2005), which renders this model 
particularly interesting for CRPC. Despite the availability of several mouse models 
generated by targeted knock-down of PTEN, only a few of these have resulted in castration-
resistant tumors that represent human CRPC. In some instances, the physical or chemical 
castration of mice has been used to generate CRPCs (Banach-Petrosky et al., 2007; Shen & 
Abate-Shen, 2007). However, it is unclear how relevant this approach is as the endocrine 
production of androgens is different in mice and men. Furthermore, carcinomas will ideally 
form only after a very long time period, related to the natural aging process of the mouse (> 
12 months). This represents a logistic restriction for the availability of such tumors/cell lines 
for larger scale experimentation.  
Simultaneously, addressing the most AR-associated pathways (PI3K, AKT, mTOR) is 
incomplete without simultaneously incorporating upstream aspects of RTK signaling on 
these pathways and AR. The most relevant RTKs are most likely EGFR, ERBB2/Her2, IGF1R 
and the c-MET/HGF Receptors. In connection with AKT and PI3K activation, these RTK’s 
and signaling modifiers like IGFBP2 (Mehrian-Shai et al., 2007) are important for the 
development and progression of PrCa; however their mutation spectrum and relevance in 
PrCa and CRPC is not very well established. Most critically, there are no PrCa animal 
models available yet that would systematically address these signaling mechanisms for 
generation of GEMMs. Oncogenic signaling and crosstalk through different RTK’s, the 
variable functions and shifting roles of RTK’s during therapy, tumor cell selection and the 
development of resistance, are likely to represent key mechanisms for target validation in 
anti-cancer therapy. Among the kinase receptors, the c-MET/HGF receptor pathway 
represents a particularly interesting target for CRPC and there is a need to recapitulate its 
molecular role by advanced model systems. Like EGFR, c-MET signaling appears to play a 
key role in many aspects of PrCa pathology (Szabo et al., 2011; Tu et al., 2010), particularly 
in regulating tumor cell motility, invasion and metastases (Pisters et al., 1995) as well as 
epithelial-to-mesenchymal transition (EMT). Furthermore, c-Met/HGF signaling is 
possibly involved in the maintenance of cancer-initiating (stem-) cells and stem cell 
proliferation (Eaton et al., 2010; Pfeiffer et al., 2011). 
2.4 Modeling tumor cell heterogeneity and mechanisms involved in cancer initiating 
or stem cells  
An increasing amount of evidence implies a role for many additional mechanisms in 
progression to therapy-resistant cancers. This includes the overexpression of anti-apoptotic 
genes (Bcl-2 or Mcl-1, BIRC5/survivin), induction of the MDR (multi drug resistance) 
transmembrane pumps, activation of NF-B, STAT2/3, and integrin-linked survival 
pathways (Weaver et al., 2002). These pathways may be critical for at least subsets of 
CRPCs. Cells that utilize additional survival mechanisms successfully may be strongly 
selected for under the conditions of anti-cancer treatment, and are likely to contribute to 
resistant cell clones. They are also likely to contribute to the generation of tumor cell 
heterogeneity before, during and after anti-cancer therapy. A spectrum of cellular factors 
like aneuploidy, differentiation and epigenetics are apparent in tumor tissues. Both genetic 
and non-genetic heterogeneities are likely to contribute to the clonal selection of resistant 
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tumor cells and/or tumor stem cell populations (Brock et al., 2009; Shackleton et al., 2009). 
Additional levels of heterogeneity are added by the cell populations from the tumor 
microenvironment (fibroblasts, myoepithelial cells), the immune system (monocytes, 
macrophages), and endothelial cells. During anti-cancer treatment, the hierarchical 
organization of tumors and their homeostatic regulation changes significantly. Together 
with the generation of genetically different clones, both aspects give rise to increasingly 
tumorigenic tumor cells & therapy resistance. The tumor context, tumor-host interactions 
and co-evolution with stromal components (Karnoub et al., 2007; Weinberg, 2008) are 
therefore critical aspects to understand clonal evolution and the nature of the resistant 
cells (Sawyers, 2007). However, there is a fundamental lack of reliable model systems to 
monitor dynamic changes in tumor & stromal heterogeneity (Marusyk & Polyak, 2010). 
The need for better systems to monitor epithelial plasticity is evident (van der Pluijm, 
2011; Wang & Shen, 2011).  
Alternatively, it has been suggested that residual disease and tumor relapse may be 
largely based on the long-term survival of cancer-initiating cells (CICs) or cancer stem 
cells (CSCs). These rare and mitotically rather inactive cell populations have been 
suggested to persist during therapy, while the bulk tumor mass may yet be largely 
diminished. Stem cell populations may be intrinsically more resistant to chemotherapy 
(Diehn & Clarke, 2006; Diehn et al., 2009), and CICs may naturally acquire invasive 
properties, e.g. by undergoing EMT. CICs may therefore be largely identical to 
metastasis-initiating cells (MICs) (Mani et al., 2008; Polyak & Weinberg, 2009). In PrCa, 
the nature of CIC/CSCs and their association with EMT (Dunning et al., 2011) is debated. 
While it is widely accepted that PrCa contains a functional stem compartment, the 
molecular characteristics of CSCs remains unclear. It is not even established if these stem 
cells are of luminal or basal phenotype (Maitland et al., 2011). According to this 
uncertainty, there is a lack of appropriate and accepted models that address the biological 
relevance of CSC populations experimentally. The most relevant information may be 
derived from mouse models, while a role for stem cells in cell lines is even more debated. 
Some mouse models point to a rare luminal cell type (Wang et al., 2009b), while others 
describe molecular profiles more consistent with a basal and/or mesenchymal phenotype 
(Frith et al., 2010a; Giannoni et al., 2010; Kong et al., 2010), which is consistent with 
observations in the breast cancer field. Some models, such as tumor spheroid 
(“prostaspheres”) cultures and non-adherent growth conditions, promote CSC properties 
and result in enhanced self-reproduction potential (Rybak et al., 2011; Watanabe & 
Takagi, 2008). This technique is now routinely used to enrich CSCs from mouse models 
(Liao et al., 2010a; Liao et al., 2010b) and human cell lines alike. Isolation of CSC 
populations from primary tumors (Guzman-Ramirez et al., 2009) and xenografts by serial 
passage of spheroids (Patrawala et al., 2006; Tang et al., 2007) or FACS reproducibly result 
in tumorigenic cancer-initiating cells. Their properties are similar to those generated by 
treatment with arsenic (Tokar et al., 2010a; Tokar et al., 2010b). The ultimate test for CSC 
characteristics is the inoculation of a limiting number of cells subcutaneously or into the 
mouse prostate, resulting in formation of tumors – although there are not as many studies 
compared e.g. to breast cancer CSCs (Al-Hajj et al., 2003; Dontu et al., 2005). It has been 
criticized that such assays may be an oversimplification and could simply select for the 
most tumorigenic cell populations. These may or may not coincide with CSC populations. 
The continuous debate indicates that also here, a lack of appropriate models (and 
biological understanding) limit the progress of drug discovery. Nude mouse models 
www.intechopen.com
 Prostate Cancer – From Bench to Bedside 
 
64
(NOD/SCID) commonly used for inoculation experiments are far from fully representing 
the complexity of human malignancies. Generally, these models critically lack immune 
cells and lymphocyte-related cytokine/chemokine secretion. Furthermore, in xenografts, 
human cancer cells become rapidly associated with mouse fibroblasts. Even co-
inoculation of cancer cells with human fibroblasts typically results in their rapid, effective 
replacement with mouse mesenchymal cells. Cell-cell interaction of human tumor cells 
with human stromal cells can therefore not be investigated. This poses a particular 
problem to the investigation of molecular pathways such as c-Met/HGF signaling (Tu et al., 
2010; Yap & de Bono, 2010), in which the ligand is typically secreted by the stromal cells, 
while the receptor is expressed exclusively on the epithelial cancer cells. This represents a 
notorious problem for the validation of inhibitors and diagnostic tools alike (Knudsen & 
Vande Woude, 2008; Knudsen et al., 2009). Alternatively, it may be recommended to explore 
such pathways by mouse cells, accepting species-to-species differences. This will 
nevertheless assure that receptor-ligand interactions are fully functional. Tissue 
recombination approaches may also be very informative. The roles of non-genetic 
heterogeneity in clonal selection, and the various CIC concepts do not have to be mutually 
exclusive; both aspects may contribute to tumor cell resistance and failure of therapy.  
3. In vitro models for prostate cancer 
3.1 Two-dimensional monolayer culture: Cell lines and primary cells 
Conventional 2D monolayer cell culture in combination with models like wound healing 
assays and transwell migration assays (Boyden chambers) have traditionally been the 
most straightforward and simplistic model systems for PrCa in vitro. This is due to the 
uncomplicated cell culture on plastic surfaces under controlled, and highly artificial 
environment. In vitro cell culture systems can be classified into two types: 1) cell lines, 
which have an unlimited proliferation capacity; 2) primary cell cultures directly 
established from human tissues. Cell lines are widely used in every aspect of cancer 
research and clearly represent the most common models. Cell lines have the big technical 
advantage of infinite reproducible quality (Rhim, 2000). Their growth properties and 
phenotypes are essentially dictated by the genetic background, which is largely defined 
by the genetic background of the original tumor. Therefore, different cell lines may show 
strong inconsistencies or contradictions that can be attributed to differences in the genetic 
wiring. These may nevertheless be representative of different stages and aspects of PrCa 
progression or differentiation (van Bokhoven et al., 2003b; Yu et al., 2009). The spectrum of 
mutations found in breast cancer cell lines was shown to be largely overlapping with 
primary cancers (Lin et al., 2007; Wood et al., 2006; Wood et al., 2007), although no such 
studies were performed for PrCa. If not single lines, at least panels of multiple PrCa lines 
may therefore be relevant for many experimental approaches. One problem with PrCa lines 
is the poor representation of the basal versus luminal phenotype that is characteristic for 
normal prostate versus PrCa tissues. Most PrCa cell lines are routinely cultured in media 
with 5 – 20% bovine calf serum, which strongly promotes the luminal phenotype. This is 
characterized by expression of the cytokeratins CK8, CK18, AR, and androgen-dependent 
genes. In contrast, most non-transformed, normal and immortalized prostate-epithelial lines 
are cultured in serum-free media. This strongly promotes the basal phenotype (Litvinov et 
al., 2006b; Uzgare et al., 2004), characterized by lack of AR expression and keratins CK5, 
CK6, CK7 and CK14. Luminal cell lines will stop proliferating in serum-free media, while 
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basal cell lines may adapt to serum-containing conditions, but still fail to undergo a luminal 
differentiation or start expressing AR. Therefore, it is questionable if basal-type primary 
cells and non-transformed prostate lines (RWPE-1, PWR-1E, or EP156T) are good models for 
clinical aspects of prostate cancers (Kogan et al., 2006; Tokar et al., 2005), as the luminal 
compartment is typically lost in malignant PrCa’s (Litvinov et al., 2006b). Furthermore, the 
immortalization of primary prostate-epithelial cells with tumor-virus oncogenes (SV40 T-
antigen, HPV-16 E6 and E7) typically results in rapid tumorigenic conversion. In contrast, 
the use of recombinant human telomerase has been demonstrated as far less compromising 
(Kogan et al., 2006; Kogan-Sakin et al., 2009). The resulting hTERT-immortalized cell lines 
retain much of their original differentiation potential, and do not accumulate additional 
genetic alterations.  
Only an estimated 30 PrCa cell lines have been described, which were derived from 
clinical prostate cancer patients. However, only a small set of these cell lines has been 
widely used in cancer research. This also means that a large number of findings and 
scientific publications is based on a very small number of models. In particular, the three 
spontaneously established cell lines, PC-3, DU-145 and LNCaP, represent by far the most 
commonly used cell culture models (Sobel & Sadar, 2005a; Sobel & Sadar, 2005b), with 
close to 10.000 publications altogether. The first PrCa cell lines PC-3 (Kaighn et al., 1978; 
Kaighn et al., 1979) and DU-145 (Mickey et al., 1977; Stone et al., 1978) were established in 
1978 and are still widely used. Both PC-3 and DU-145 have been cited in over 3000 
publications. PC-3 cells were isolated from a human PrCa bone metastasis and have a 
very high metastatic potential (Kaighn et al., 1979), a property that has resulted in a large 
number of xenograft studies based on PC-3 cells inoculated typically into SCID nude 
mice. These xenografts are characterized by robust growth and rapid tumor formation. 
However, PC-3 cells are androgen-insensitive and lack expression of the AR protein. Loss 
of AR expression in PC-3 cells is likely related to epigenetic silencing of the AR locus. PC-
3 cells may therefore represent a genuine subpopulation PrCa cells with naturally absent 
AR expression, characterized by very high cancer-initiating capacity possibly related to 
CSC. Interestingly, despite the lack of AR expression, PC-3 cells are capable of undergoing 
near complete acinar morphogenesis upon embedding in laminin-rich ECM (Matrigel). 
This argues for the substantial differentiation potential of PC-3 cells and in favor of their 
biological relevance (Härmä et al., 2010). Despite continuous ex-vivo culture on plastic 
dishes for over three decades, PC-3 cells have retained an amazing potential for epithelial 
maturation. Re-expression of AR in PC-3 cells can either suppress or slightly promote cell 
proliferation, depending on which promoter drives the expression of the AR protein 
(Altuwaijri et al., 2007; Litvinov et al., 2006a; Yuan et al., 1993). Additionally, PC-3 cells 
retain the co-activator profiles required for fully functional androgen signaling (Litvinov 
et al., 2006a). Nevertheless, such experimental strategies have to be taken carefully as they 
potentially contradict the genuine biological properties of a cell line. 
Similar to PC-3, DU-145 cell were derived from a brain metastasis of human PrCa (Stone et 
al., 1978). Like PC-3, these cells are androgen-insensitive and lack expression of AR protein 
due to epigenetic silencing of the AR promoter by CpG island methylation that has shut off 
the expression (Chlenski et al., 2001; Yu et al., 2009). DU-145 cells show a similar, strong 
differentiation potential analogous to PC-3 cells when embedded in Matrigel. In both cases, 
a significant capacity for epithelial maturation has been retained for three decades of ex vivo 
culture. Stable transfection of functional human AR into DU-145 cells results in cells with 
reduced proliferation rate. When DU-145/AR cells are treated with testosterone, 
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proliferation rate and other properties are restored, implying that AR can still function as a 
regulator of proliferation of DU-145-AR cells (Scaccianoce et al., 2003). Taken together, both 
PC-3 and DU-145 cells represent interesting models, despite the lack of AR expression - 
although we lack a complete understanding of their biology and relevance for clinical PrCa. 
The LNCaP cell line followed in 1980 (Horoszewicz et al., 1980; Horoszewicz et al., 1983) and 
has since resulted in over 5000 peer-reviewed publications alone. The LNCaP cell line was 
isolated from a lymph node metastasis, and contains a gain-of-function mutation commonly 
found in many clinical CRPCs (T877A). LNCaP cells are therefore a genuine and relevant 
model for CRPC (Yang et al., 2005). Down-regulation of AR in LNCaP cells by siRNA inhibits 
cell growth and increases the level of apoptosis (Compagno et al., 2007; Eder et al., 2000; Yang 
et al., 2005; Yang et al., 2005). This is suggesting that LNCaP are addicted to oncogenic variants 
of AR which act as a key survival factor; a characteristic or CRPC.  
Newer cell line models have only been added to this small collection during the late 1990’s. 
These cell lines are typically derived from xenograft models, such as the 22rV1 and CWR-r1 
lines which are both derivatives of the CWR22 xenograft (Sramkoski et al., 1999). Similarly, 
the PC346 panel of cell lines was derived from a human xenograft and has been developed 
into a comprehensive series of derivative cell lines that mimic many aspects of progression 
to CRPC (Marques et al., 2006; Marques et al., 2010; Vlietstra et al., 1998) and resistance 
against anti-androgens. The PC-310 and PC-82 cell lines represent similar models (Jongsma 
et al., 2000). Another panel of more recently developed and functionally relevant PrCa cell 
lines (MDA-PCa-2a , MDA-PCa-2b) was established from bone metastases of a single patient 
in 1999 (Navone et al., 1997; Zhao et al., 1999). Similarly, the DuCaP (Lee et al., 2003; Lee et 
al., 2001) and VCaP (Korenchuk et al., 2001) cell lines were established from soft tissue and 
bone metastases, respectively, of the same CRPC patient in 1999. DuCaP and VCaP 
currently represent the only relevant models for ETS fusion factor positive PrCa. VCaP and 
DuCaP are also the only PrCa cell lines that harbor a wild type, but amplified and 
overexpressed AR gene, a hallmark of CRPC. Both VCaP and DuCaP cells have been 
successfully used for xenograft models, mimicking cancer-stromal cell associations and 
stem-cell biology (Cooper et al., 2003; Pfeiffer et al., 2011). A specialty of DuCaP cells is their 
dependency on co-existing mouse fibroblasts, which represent a carry-over from the growth 
of these cells in xenografts. However, the dependency of DuCaP cells on the mouse stromal 
counterpart can be broken, resulting in a morphologically very different phenotype.  
Although additional PrCa cell lines are also available, detailed studies have revealed that 
many of these are in fact derivatives of the other cell lines or even non-prostatic lines (Sobel 
& Sadar, 2005a; Sobel & Sadar, 2005b; van Bokhoven et al., 2003b).  
The few bona fide cell lines, almost all derived from metastases, do not span the complete 
range of PrCa phenotypes, and are not fully representative of primary PrCa. It is therefore 
not surprising that until very recently, the lack of a variety in PrCa cell lines has probably 
contributed to the failure of most small molecule inhibitors against CRPC in clinical trials. A 
few cell lines derived from benign prostate hyperplasia have also been established (Chu et 
al., 2009; Cunha et al., 2003). It cannot be excluded that long-term culture changes the 
biological properties of a cell line, a problem that is confounded by the mismatch-repair 
deficiency observed in many cell lines. Therefore, primary cultures of malignant prostatic 
cells and their normal epithelial counterparts would be in principle preferable (Peehl, 2005) 
to cell lines. As the interest in “personalized medicine” is rising, well defined primary 
material from clinically interesting cases would be expected to provide an excellent 
opportunity to follow up specific questions experimentally. Primary cell cultures from 
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clinical tissue specimens indeed offer a number of biological advantages, and are often 
considered to better reflect the characteristics of the original tissues. However, primary 
cultures are usually derived from primary adenocarcinomas, unlike PrCa cell lines that have 
been typically generated from metastases of CRPCs (Maroni et al., 2004; Peehl, 2005). These 
may therefore represent biologically different entities. Furthermore, primary cell cultures 
present significant technical difficulties because of the limited access, restricted lifespan and 
requirements for specific culture techniques. Thus, only very few studies have made use of 
series of primary prostate cancer cells for experimentation (Eaton et al., 2010; Guzman-
Ramirez et al., 2009). At the same time, the intrinsic heterogeneity of primary tissues poses 
many challenges, and a relatively large number of clinical samples will have to be 
processed. The isolation of primary cell material from samples is notoriously difficult. In 
practical experience, isolation and even short-term cultivation will fail in the majority of 
cases. Unrestricted access to primary clinical material is critical to overcome these many 
limitations, but may also pose a logistic problem. The availability of dedicated and 
experienced personnel at the clinical site to systematically collect, process and store such 
material is mandatory. The clinical partners also have to properly address and document 
questions concerning tumor grading and staging, therapy response etc., patient relapse and 
survival. These represent invaluable data for bringing tumor cell behavior into the correct 
and clinically relevant context.  
Normal human prostate epithelial cells and even primary PrCa cells often undergo 
approximately 10 - 30 population doublings, before they become senescent (Peehl & 
Feldman, 2004; Sandhu et al., 2000). This could point to the possibility that immortalization 
is not necessarily a prerequisite for PrCa growth in vivo, and may represent a good 
explanation for the difficulties in generating PrCa lines in the past. Despite these difficulties, 
analyses of tumor suppressor activity, gene expression and cytogenetics in primary cultures 
have unraveled many critical changes that are important for PrCa progression. Challenges 
that remain to be addressed before tapping the full capacity of primary cell culture as a 
reliable model system include standardized and greatly improved isolation methods, the 
unequivocal characterization of cancer- and normal epithelial stem cells, and the successful 
induction and maintenance of a differentiated androgen-responsive phenotype (Miki & 
Rhim, 2008; Peehl, 2005). The isolation of cancer- or normal associated fibroblasts is a 
different issue and usually considerably less complex.  
3.2 Organotypic 3D culture models 
In monolayer culture of PrCa lines, cells lose important and biologically very relevant 
properties like differentiation, cellular polarization, cell-cell communication and extra 
cellular matrix (ECM) contacts. Simultaneously, wound healing, inflammation, and hyper-
proliferation are artificially promoted – which is the main reason why 2D monolayer cell 
culture only poorly represents tumor cell biology in vivo. Accordingly, the most effective 
small molecule inhibitors and chemotherapeutic drugs in 2D monolayer settings primarily 
target cell proliferation and mitosis. Other interesting drugs that may affect differentiation-
related pathways or small cell populations instead of the rapidly promoting tumor bulk, are 
likely to go undetected in cell-based screens using monolayer cultures. Such drug 
candidates may be connected to cell-cell interaction, maturation, EMT and cancer stem cell 
turnover - aspects that that incompletely recapitulated in 2D monolayer culture. In the pre-
clinical phase of drug discovery, this bias results in an unnecessary low predictive value of 
many in vitro experiments.  
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The culture of glandular epithelial cancer cells in a certain tumor microenvironment consisting 
of purified ECM, such as collagen, hydrogels or Matrigel, was established over two decades 
ago (Streuli et al., 1991; Weaver et al., 1995; Weaver et al., 1996), and initially based mainly on 
breast cancer models. Matrigel represents a reconstituted, laminin-rich basement membrane, 
which supports cell polarization, cell-cell- and cell-matrix interaction, and promotes re-
expression of differentiation markers even in transformed lines (Bissell & Radisky, 2001; 
Streuli et al., 1995). Glandular epithelial cancer cells rapidly adapt to different 
microenvironments and can dynamically switch between alternative pathways that regulate 
proliferation, differentiation and survival. When embedded in an ECM like Matrigel or 
collagen, normal prostate epithelial cells differentiate into hollow polarized spheroids, 
characteristic for functional, glandular epithelial cells (Simian et al., 2001; Xue et al., 2001a; Xue 
et al., 2001b). They also develop a pronounced motility and rapidly re-populate the available 
space by branching and acinar morphogenesis. Similar to normal epithelial cells, PrCa cells can 
also move and invade the surrounding Matrigel, although their mode of migration is 
phenotypically different from the formation of collective, multicellular sheets or tubes of cells 
observed in normal cells (Fig. 2)(Friedl & Wolf, 2008). The phenotype of cancer invasion 
strongly depends not only on the cells, but also on the composition and density of the ECM, 
and can vary from amoeboid blebbing, mesenchymal fibroblast-like motility and multicellular 
streaming or chain migration (Friedl & Wolf, 2010). 3D models of tumor-cell invasion are 
thought to properly represent many aspects of cellular dynamics inside actual tumors, as the 
cells can utilize a comparable mode for sliding and squiggling through the mesh of the ECM 
(Fig. 3)(Wolf & Friedl, 2006; Wolf et al., 2007). Invasion in 3D is assisted by proteolytic 
processes and proteases (Friedl & Wolf, 2009; Wolf & Friedl, 2009) and soluble factors 
(Gaggioli et al., 2007). Furthermore, cell motility and invasion is also controlled by intrinsic 
physiological factors, such as re-organization of the cytoskeleton (Medjkane et al., 2009; Sanz-
Moreno et al., 2008). The potential to undergo an EMT and to acquire mesenchymal migration 
modes is a critical aspect that is thought to contribute to PrCa invasion (Acevedo et al., 2007; 
Chu et al., 2009; Sequeira et al., 2008). Despite the need for 3D scaffolds, the most widely used 
cell culture models for tumor cell invasion are still comparably artificial assays such as 
transwell invasion assays (Boyden chambers), and wound healing/scratch wound migration 
assays. However, tumor cell migration in these models still occurs in essentially two 
dimensions. Any representative 3D invasion model that mimics motility inside the tumor 
microenvironment represents a significant improvement (Brekhman & Neufeld, 2009). 
Furthermore, 3D matrices more faithfully recapitulate genuine invasive pro-processes such as 
invadopodia formation (Harper et al., 2010; Wolf & Friedl, 2009), and embryonal, 
developmental processes that may be relevant also for cancers such as aspects that may be 
branching morphogenesis (Andrew & Ewald, 2010; Xue et al., 2001a; Xue et al., 2001b). The 
development of drug resistance also profits from appropriate 3D cell culture models. Drug 
resistance appears to be concomitant with increased cell motility and trans-differentiation 
features like EMT (Gupta et al., 2009; Kalluri & Weinberg, 2009; Reiman et al., 2010) also in 
PrCa (Armstrong et al., 2011; Giannoni et al., 2010; Kong et al., 2010). EMT has been intensely 
discussed as a key mechanism for future therapeutic options (Dunning et al., 2011) in PrCa. 
EMT and stem cell properties go together with metastatic potential (Chang et al., 2011; Li & 
Tang, 2011; Ling et al., 2011; Liu et al., 2011) and link EMT with the problematic of distant 
metastases. Also CTCs have been found to display properties of EMT, invasiveness and stem 
cell characteristics (Armstrong et al., 2011). To cover these morphologic and dynamic aspects 
properly, requires the combination of appropriate biologically relevant scaffolds that mimic 
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the tumor microenvironment, with appropriate cell lines (or primary cells) that show invasive 
properties. This could be counterbalanced by their variable differentiation potential, as 
epithelial maturation counteracts cell motility. Using such improved models, the screening for 
novel anti-cancer drugs can eventually enter a new phase. Researchers should increasingly 
utilize well characterized 3D organotypic model systems to explore the effects of drugs and 
targets in multicellular organoids. Appropriate models should also be cost effective and must 




Fig. 2. Prostate adenocarcinoma cells in 3D laminin-rich microenvironment. Some PrCa cells 
bear the ability to differentiate into multicellular acinar structures with strong cell-cell and 
cell-ECM contacts (illustrated here with beta-catenin and laminin alpha-1 immunostainings). 
Invasive PrCa cells move by actively degrading the surrounding lrECM and tend to be less 
restricted by cellular contacts. 
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Fig. 3. An overview of three different in vitro models for PrCa: 2-D monolayer co-culture, 
low-attachment culture of prostaspheres, and organotypic 3-D culture. 
In the pre-clinical phase of drug discovery, the question of drug response & resistance is 
routinely addressed by tumor xenograft models, mainly utilizing classic tumor cell lines and 
nude mouse models. While in vivo models may well overcome many of the shortcomings of 
2D cell culture, they are time consuming, expensive, and require ethical considerations 
and permissions. Nude mouse models possess no immune system, and poorly mimic the 
critical aspects of inflammation, tumor microenvironment, human endocrine specialities 
and morphology, and often fail to mimic tumor metastasis. Xenograft models only allow 
remote sensing, followed by post-experimental histology. With few exceptions (in vivo 
imaging), animal experimentation gives no direct mechanistic insights into dynamic 
interactions between different cell types within a tumor at the cellular level. Monitoring 
inducible changes in real time is a key problem, potentially addressed in the future by tissue 
slices (Sonnenberg et al., 2008; van der Kuip et al., 2006). Until tissue slices may become firmly 
established, other models could represent a valid alternative. Therefore, 2D and xenograft 
experiments can be readily complemented by organotypic assays. These methods, which are 
still in development in PrCa, generate highly valuable functional data for drug discovery. 
Validated 3D models may also help to reduce animal experimentation and associated cost (3R 
strategy: “Replacement, Refinement and Reduction of Animals in Research”). Political 
pressure from the European Commission to reduce animal experimentation in Europe could 
further contribute to a wider acceptance of organotypic models in drug discovery. Advanced 
and well-characterized 3D models may give important clues for lead prioritization and allow 
significantly cutting the need for animal experiments, - for example if compounds successful 
identified in 2D screens are completely ineffective in subsequent 3D organotypic assays. 
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Generally, 3D cell aggregates (spheroids, prostaspheres, etc.) tend to show considerably 
higher drug resistance compared to 2D cultures. Such comparisons may result in a vastly 
different dose-response curve, ideally closer to the expected in vivo data. However, to 
firmly establish organotypic models and to validate their relevance in the pre-clinical phase 
of drug discovery, systematic side-by-side comparisons between in vivo and in vitro models 
would be required. These efforts are currently starting.  
The biological relevance of functional screens conducted in 3D organotypic cultures strongly 
depends on information that can be concluded from associated assays. In routine cell-based 
screens, mostly indirect assays measuring overall cell viability and proliferation are used. 
Less frequent is the use of measurements based on biomarkers (e.g. Ki67; antibody 
stainings, immune fluorescence) or morphological parameters (imaging). These options 
are central for 3D organotypic cultures; the most important parameters for evaluating 
drug responses will be based on multicellular morphology. To functionally validate 3D 
organotypic models in cancer biology, high content microscopy based on morphological 
features will have to be combined with automated image analysis tools (Han et al., 2009; 
Han et al., 2010). This combination will allow real-time monitoring of dynamic changes in 
spheroid morphology as a readout. Automated image analysis of 3D cultures relies on 
measuring morphological parameters such as size, shape, differentiation, density, surface 
structures and invasive properties of spheroids. Consistent morphological changes in 
response to perturbants (small molecule inhibitors, siRNAs, stress conditions) can then be 
statistically evaluated and quantified. Apoptosis and cell proliferation can also be readily 
evaluated based on live-cell staining with reactive dyes. These processes are difficult to 
automate, and represent the key bottlenecks to overcome for larger scale screens. The use 
of GFP-tagged cell lines (combined with luciferase) represents a widely established tool 
that can be utilized in both in vivo and in vitro, organotypic settings. The same tagged 
cells can be used for in vivo and microscopic imaging, and could facilitate the much 
needed side-by-side comparisons of organotypic models with mouse models. Novel 
assays to monitor specific mechanistic changes will become important to quantify critical 
aspects of pharmacology and to evaluate acute drug responses. The field of live-cell assay 
development, including reactive dyes and reporter constructs, is a key aspect of HCS in 
the pharmaceutical industry but has yet to make the move into 3D models. There is a lack 
of informative assays for monitoring the activity of key pathways such as NF-B, AKT, 
PI3K or Wnt in living cells. Such assays would also enable researchers to monitor cellular 
heterogeneity, e.g. in response to drug therapy. Single cell analysis, ideally based on live-
cell assays, is already a powerful tool in many aspects of biology. This could also allow 
researchers to identify and monitor putative stem cell populations, and quantify their 
dynamics in anti-cancer treatments. Imaging is also critical to make sense of the dynamics 
of co-culture experimentation which will be discussed later. 
3.3 Non-adherent 3D culture of prostaspheres and bioreactors 
Early studies by Kinbara et al (Kinbara et al., 1996) demonstrated that prostate epithelial 
cells, isolated from different lobes of the adult rodent prostate, exhibited stem cell like 
features, including an enormous proliferative potential and the potential for re-programmed 
epithelial differentiation. Regenerative capacity, attributed to only a small population of 
pluripotent progenitor epithelial cells, is rapidly lost when the cells are placed in monolayer 
culture or embedded in Matrigel. However, “stemness” can be strongly promoted and 
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maintained by non-adherent cell culture, e.g. as spheroids. The first such approaches were 
described as “liquid overlay” technology, which prohibits successful cell attachment. Cells 
are then forced to adhere to themselves to overcome the lack of critical survival signals 
provided by cell and matrix adhesion, and to avoid anoikis or apoptosis. Low-attachment 
technologies have been introduced multiple times, e.g. by Poly-HEMA coated plastic plates. 
Placing prostate epithelial cells in non-adherent culture e.g. on a layer of hydrogel has a 
similar effect, resulting in the formation of spheroids or “prostaspheres” (Fig. 3)(Sauer et al., 
1997; Sauer et al., 1998; Wartenberg et al., 1998). Such spheroids undergo a dynamic process 
of de-differentiation and reproducibly acquire properties of stem- and precursor cells 
(Patrawala et al., 2007; Pfeiffer & Schalken, 2010; Tang et al., 2007). Spheroid culture 
represents one of the oldest in vitro cell culture technologies and was pioneered already 
over 40 years ago by Sutherland et al (Sutherland et al., 1971; Sutherland et al., 1977).  
Prostaspheres can be easily generated from most PrCa cell lines (Rajasekhar et al., 2011; 
Rybak et al., 2011), and serially passaged. Prostaspheres exhibit increased expression of 
putative stem cell markers, and represent 3D clusters of tumor cells derived from one or 
several cell clones that develop into multicellular globes of fairly large size. Spheroids often 
contain different subpopulations of cells that can be quiescent, hypoxic and necrotic and 
display a spatial geometry which provides a number of practical experimental advantages 
over adherent cell culture (Freyer & Sutherland, 1980; Kostarelos et al., 2004; Sutherland, 
1988). To date, prostaspheres (and mammospheres, the equivalent in breast cancer cells) 
represent a widely used tool to study the processes of self-renewal, differentiation and 
cancer stem cell research (Lang et al., 2009). An intriguing recent application is the 
combination of spheroid culture to enrich for human prostate progenitor cells rat urogenital 
sinus mesenchymal cells. Inoculation of the formed chimeric prostate tissue under the renal 
capsule of nude mice (Hu et al., 2011) leads to tumor masses with human functionality, 
indicated by expression of PSA and hormone-dependent PrCa lesions. This represents an 
elegant system for the experimental recapitulation of carcinogenesis.  
Another classic application for prostaspheres is within bioreactors (Ingram et al., 2010). 
These provide a low-turbulence environment which promotes the formation of very large 
and complex spheroids. A bioreactor is typically rotated or stirred, to provide a gentle 
mixing of fresh and spent nutrients without inducing excessive shear forces that may 
damage the structures. Bioreactors are also an ideal tool to generate co-culture spheroids, 
e.g. with stromal and epithelial/tumor cells (Yates et al., 2007a; Yates et al., 2007b), or to 
promote the self-renewal potential and stem cell characteristics (Frith et al., 2010b). 
Bioreactor research could be instrumental in helping scientists to prepare better models for 
cancerous tissues, and is expected to facilitate drug and peptide development. Improved 
characterization of these models and comparisons to other alternatives would be important 
also in this case.  
3.4 Co-culture models for the investigation of tumor-stroma interactions 
In a tumor, fibroblasts, smooth muscle cells, endothelial cells and leukocytes, interact 
physically or via the secretion of paracrine signalling molecules with tumor cells. These cell 
types make up the main components of the breast tumor microenvironment (Bissell & 
Radisky, 2001; Polyak et al., 2009; Radisky et al., 2002; Shipitsin et al., 2007). The situation in 
PrCa has also been explored in detail (Cunha et al., 2003; Cunha et al., 2004). Stromal cells 
secrete a variety of growth factors like FGF-2, FGF-7, and FGF-10 (Chambers et al., 2011), 
insulin-like growth factor (IGF), epidermal growth factor (EGF), and a panel of chemokines 
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(Kogan-Sakin et al., 2009). FGFs like FGF-10, which signals through the FGFR1 receptor, 
play a particularly critical role in regulating PrCa cell morphology and invasive properties 
(Abate-Shen & Shen, 2007; Chambers et al., 2011). Dysregulated FGF-10 expression has been 
observed in advanced PrCa and suggests the FGF-10/FGFR1 axis as a potential therapeutic 
target in treating both hormone-sensitive or CRPC (Memarzadeh et al., 2007). Exposure to 
paracrine growth factors like FGF-10 and FGF-7 may be critical for the initiation of 
oncogenic transformation (Fata et al., 2007). Additional secreted factors including 
chemokines like CCL2 act as key factors for PrCa invasion and bone metastasis (Li et al., 
2009; Loberg et al., 2006a). These and others like IL-6 are thought to support differentiation 
and stimulate cancer cell growth (Culig et al., 1995; Malinowska et al., 2009). A tumor is 
clearly the product of intricate cross-talk between the epithelial and stromal cells; with the 
secretion of cytokines and chemokines as the common language. Identification of these 
environmental, paracrine cues which induce important changes in cell fate during 
development, has caused a fundamental re-evaluation of the process of tumorigenesis.  
In vitro co-culture systems could also provide better models to address the interaction of 
epithelial AR functions in cell proliferation and metastasis (Fig. 3). For example, the 
immortalized human prostate stromal cell line WPMY-1 expresses functional AR and 
secretes paracrine growth factors (Webber et al., 1999), with an impact on the morphology 
and proliferation of the epithelial counterpart. Stromal AR expression promote epithelial cell 
invasion via paracrine secretion of growth factors, chemokines or cytokines. The stromal 
cells, via AR expression, can therefore modulate tumor cell proliferation and invasion 
(Tanner et al., 2011; Yu et al., 2011; Zhang et al., 2008). Their key effects are mediated e.g. by 
estrogen receptor signaling or the ERK kinase family, but also secreted high-molecular 
weight glycoproteins like endoglin (Romero et al., 2011). Expression of eccrine factors is 
mediated by TGF beta, another key factor and signaling pathway that massively affects the 
tumor-stroma interaction (Chambers et al., 2011; Pu et al., 2009). TGF beta dependent 
mechanisms play a key role in regulating paracrine stromal signals, and strongly affect 
epithelial cell adhesion via adhesion/cytoskeleton interactions. These and many other 
reports indicate a fundamental role for the stroma and stroma-derived secreted factors in 
maintaining adult prostate epithelial tissue morphology and integrity.  
Simple, modular and reproducible 3D co-culture systems might allow researchers to further 
address the interdependence of tumor and stromal cells in straightforward settings. These 
systems would ideally allow the analysis of morphological features and epithelial 
differentiation/maturation. Optimal systems should also be standardized and miniaturized 
to facilitate the use of imaging and automated image analysis tools, and provide a higher 
experimental throughput. Such advanced, reproducible 3D co-culture models could then be 
utilized to systematically explore the importance of molecular signalling pathways AR, 
PI3K/AKT, and c-MET on heterogeneous co-culture and tissue formation. For example, 
stable stromal-tumor co-cultures are expected to be more resistant to anti-androgens or c-
MET inhibitors than the isolated counterparts (Maeda et al., 2006; Tu et al., 2010), but this 
has not been properly investigated across multiple model systems. Which molecular and 
cell-cell interactions determine the response? Can resistance to anti-cancer therapeutics, e.g. 
androgen independence, be generated more readily in co-culture than by isolated mono-
cultures, or even better in xenografts; and which molecular changes can be identified in 
resistant populations arising? What are the differences between human and mouse 
fibroblasts in terms of heterogeneity and response to anti-cancer therapeutics (Kiskowski et 
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al., 2011)? For such fundamental questions, the use of 3D co-culture settings could represent 
a critical “missing link” between reductionist cell culture models and more complex 
xenograft experiments or even GEMMs.  
4. Conclusions 
The heterogeneous nature of PrCa has made it difficult to understand the factors involved in 
the onset and progression of the disease. Advanced in vitro experimental systems should 
ideally try to recapitulate, as closely as possible, the 3D organization of tumors and mimic 
aspects of cellular heterogeneity and tumor-host cell interactions within the tumor 
microenvironment. Other important aspects are cell motility, the dynamics of clonal 
selection and tumor cell heterogeneity generated during chemotherapy. To provide a more 
comprehensive, biologically relevant context to investigate these processes experimentally, 
an ideal situation would be to combine in vitro models (2D, 3D and co-culture), transgenic 
mouse models (GEMMs), and xenografts into a bigger picture. A maximum of information 
can be generated by the systematic comparison of multiple models. The tissue architecture 
and heterogeneity formed by these various model systems may be vastly different, but the 
ultimate standard will be to relate these morphologies to the human clinical pathology and 
histology. Although the role of pathologists has not been featured prominently in this 
review, it remains one of the key aspects for cancer biology and the drug discovery process 
as a whole.  
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